13G Filing: James E. Flynn and Mannkind Corp (MNKD)
You can access the original SEC filing by clicking here.
Posts Tagged ‘Mannkind Corp (MNKD)’
5 Stocks Hedge Funds Are Betting Against Insiders
We at Insider Monkey have consistently followed hedge funds and institutional investors to help investors earn attractive returns through equity investment.
Nektar Therapeutics (NKTR), Pfizer Inc. (PFE): What’s MannKind Corporation (MNKD) Really Worth?
This is close to the market cap that Bank of America's Steve Byrne thinks MannKind Corporation (NASDAQ:MNKD) is worth.
MannKind Corporation (MNKD), Seattle Genetics, Inc. (SGEN), Eli Lilly & Co. (LLY): A Pharmacology Primer for Biotech Investors
In pharmacology, we don't only have to consider the actions of the drug on the body.
MannKind Corporation (MNKD), Pfizer Inc. (PFE): Why Afrezza May Not Work
MannKind Corporation (NASDAQ:MNKD) has been struggling to get its inhalable insulin product Afrezza on the market; the product was sent back to the labs by the Food and Drug Administration...
Will This Destroy MannKind Corporation (MNKD)?
The drug more closely mimics how the body secretes insulin after a meal to lower blood sugar, doing its job and leaving the bloodstream quickly.
MannKind Corporation (MNKD), EXCO Resources Inc (XCO), Riverbed Technology, Inc. (RVBD): What This $18B Scandal-Ridden Hedge Fund Has Been Buying
Today, let's look at SAC Capital Advisors, run by Steven Cohen.
MannKind Corporation (MNKD): To Infinity And Beyond?
The idea inspired me to issue my own questions about the company, using the questions as a crutch to explain my position.
MannKind Corporation (MNKD), Incyte Corporation (INCY): Will This Large Biotech Pop Experience Analyst Backlash?
While I do think it's possible that MannKind Corporation (NASDAQ:MNKD)'s inhaled insulin device, Afrezza, will be approved by the Food and Drug Administration, I do have serious...
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY), MannKind Corporation (MNKD): Three New Diabetes Drugs Possibly on the Way Soon
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
MannKind Corporation (MNKD), Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS) – Attention Biotech Investors: Stop Looking at Share Price
After my article on MannKind Corporation (NASDAQ:MNKD) earlier this week, a reader wasn't too happy about my view that the company was overvalued given the most recent phase ...
Osiris Therapeutics, Inc. (OSIR), GlaxoSmithKline plc (ADR) (GSK), Forest Laboratories, Inc. (FRX): This Week in Biotech
With the SPDR S&P Biotech Index up 34% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Merrimack Pharmaceuticals Inc (MACK), MannKind Corporation (MNKD), Synta Pharmaceuticals Corp. (SNTA): Horrendous Health-Care Stocks This Week
While the major indexes pulled back this week, their declines paled in comparison to the huge drops experienced by a handful of health-care stocks.
Orbitz Worldwide, Inc. (OWW), Vical Incorporated (VICL), MannKind Corporation (MNKD): Last Week’s Biggest Losers
Let's start with Vical Incorporated (NASDAQ:VICL). The biotech shed more than half of its value after abandoning its once promising Allovectin program.
Netflix, Inc. (NFLX), Microsoft Corporation (MSFT): This Week’s Smartest Stock Moves
Yum! Brands, Inc. (NYSE:YUM)'s Taco Bell is keeping the Doritos-dusted taco shells coming.
MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer
Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive.
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
ExOne Co (XONE), MannKind Corporation (MNKD): Here’s What This $30 Billion Pension Fund Has Been Buying
Today, let's look at the California State Teachers' Retirement System ("CalSTRS"), a major pension fund that's celebrating its 100th anniversary in 2013.
Elan Corporation, plc (ADR) (ELN), VIVUS, Inc. (VVUS), MannKind Corporation (MNKD): Three Biotech Companies to Watch This Summer
The news flow from biotech companies might slow down during the summer, but it won't stop.
Who Really, Really Wants Some More Pfizer Inc. (PFE) Stock?
An entity with deep pockets is looking to buy boatloads of Pfizer Inc. (NYSE:PFE) stock. And we're talking yacht-sized boatloads -- not canoe-sized ones.
Tesla Motors Inc (TSLA) & Other Surprises That Are Beating Netflix, Inc. (NFLX) in 2013
Netflix, Inc. (NASDAQ:NFLX) has been a poster boy for market success in 2013.
MannKind Corporation (MNKD), Orexigen Therapeutics, Inc. (OREX): Two Biotech Approval Outcomes That Might Affect You
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains.
Microsoft Corporation (MSFT), QUALCOMM, Inc. (QCOM): The Dow’s Triple-Digit Gains Left These Stocks Behind
Investors can never predict whether the market will rise or fall on any given day, but lately, a pretty good bet has been to expect some substantial volatility in one direction...
Why MannKind Corporation (MNKD) Is Poised to Pull Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company MannKind Corporation...
Bristol Myers Squibb Co (BMY), Momenta Pharmaceuticals, Inc. (MNTA): White Collar Criminals Love Biotech Stocks
It's understandably very tempting for people with inside information to trade biotech stocks.
MannKind Corporation (MNKD) Still Treading Water, So Why Are Investors Surfing?
You could say that MannKind Corporation (NASDAQ:MNKD) is treading water a bit these days -- at least from the outside perspective.
MannKind Corporation (MNKD), Sarepta Therapeutics Inc (SRPT): Why You Shouldn’t Buy Stocks in Biotech
How can you double your investment literally overnight? Buy stocks of the right biotech companies.
Aegerion Pharmaceuticals, Inc. (AEGR), MannKind Corporation (MNKD): 3 Biotech Companies You Should Have Bought This Year
If you'd owned these three biotech companies at the beginning of the year, you're sitting on around a triple compared to a relatively smaller-but-still-impressive 34% increase...
MannKind Corporation (MNKD)’s Run to Glory
Shares of MannKind Corporation (NASDAQ:MNKD) have nearly tripled over the last year.
MannKind Corporation (MNKD), PDL BioPharma Inc. (PDLI) & Optimer Pharmaceuticals, Inc. (OPTR): 2 Biotechs to Avoid, 1 to Buy
Keeping a close eye on two particular classes of investors can tell you a lot about how stocks might move in the future.
MannKind Corporation (MNKD): Why Have Shares Moved?
MannKind Corporation (NASDAQ:MNKD) took one giant leap over the past few days.
Vertex Pharmaceuticals Incorporated (VRTX): What You Need To Know
What's the source of your investment strategy? Many look to great investors like Warren Buffett for guidance on how to invest.
MannKind Corporation (MNKD): Should You Buy?
Perennial underdog MannKind Corporation (NASDAQ:MNKD) could be on its countdown to liftoff.
Vertex Pharmaceuticals Incorporated (VRTX), MannKind Corporation (MNKD): Want to Invest in Biotech? Think Like a Venture Capitalist
They're demanding. They take risks -- but only calculated ones. And they ask lots of penetrating questions to understand as much as possible before putting a dime on the line.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE) and Big Pharma Led the Dow Jones Industrial Average (.DJI) to New Highs Today
Investors have been as clear as they can be about what they see as their ideal situation.
Sarepta Therapeutics Inc (SRPT), Keryx Biopharmaceuticals (KERX), MannKind Corporation (MNKD): Three Speculative Biotech Companies Primed to Pop
They don't have any products on the market. They have little or no revenue. Earnings? Nada. Many people are betting that they will fail.
3 Bio-Techs Insiders Love: Sequenom, Inc. (SQNM), Infinity Pharmaceuticals Inc. (INFI), MannKind Corporation (MNKD)
The biotechnology industry has given exceptional returns in the last couple of years. Quite a few stocks have soared due to FDA approval of their respective drugs.
What’s Behind MannKind Corporation (MNKD)’s Incredible Run? – Pfizer Inc. (PFE)
After seeing MannKind Corporation (NASDAQ:MNKD) rocket upwards over the last week, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to ...
Whoa! These 3 Stocks Are Outpacing the Dow’s Run: Research In Motion Ltd (BBRY), MannKind Corporation (MNKD), Dex One Corporation (DEXO)
Wash. Rinse. Repeat. The Dow Jones Industrial Average is making hitting new highs look easy these days, and no longer does it have to make dramatic jumps to do so, either.
3 Biotechs Still Burning Through Cash: Ariad Pharmaceuticals, Inc. (ARIA), Dynavax Technologies Corporation (DVAX), MannKind Corporation (MNKD)
Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue.
3 Events Biotech Investors Need to Watch in 2013: Vical Incorporated (VICL) and More
It's make-or-break time in 2013. That's the situation for several biotech companies with critical phase 3 trials under way.
Why No One Cares About MannKind Corporation (MNKD)’s Earnings
MannKind Corporation (NASDAQ:MNKD) announced earnings results on Monday, but no one cares. Don't get me wrong. Plenty of people are intensely interested in MannKind.
Whoa! What Just Happened to My Stock? MannKind Corporation (MNKD), Zynga Inc (ZNGA)
The Dow Jones Industrial Average ended last week on a high note, closing up almost 50 points, but that put it at about the same spot where it ended the week before, though slightly...
